BG Medicine Inc. (NSDQ:BGMD) signed yet another deal involving its galectin-3 heart failure test, this time with Boston Scientific Corp. (NYSE:BSX)
The Natick, Mass.-based cardiac device giant is studying whether Waltham, Mass.-based BG’s diagnostic can identify patients in need of cardiac-resynchronization therapy using patient data from its Madit-CRT clinical trial.